Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Date:3/28/2009

Data provide support for expected Phase 3 program

CRANBURY, N.J., March 28 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal(TM) (migalastat HCL) for Fabry disease. The results will be presented at the American College of Medical Genetics (ACMG) 2009 Annual Meeting in Tampa, FL.

Phase 2 Extension Study Overview:

Twenty-six subjects completed either 12 or 24 weeks of treatment during Phase 2 studies. Twenty-three of the 26 subjects continue to receive treatment in an ongoing extension study designed to evaluate the long term safety and efficacy of Amigal. Ten of the 23 subjects have been on treatment for at least 2 years and 4 subjects have been on treatment for more than 3 years.

Preliminary Results:

Treatment with Amigal was generally well-tolerated, with no drug-related serious adverse events. The most common adverse events were headache, arthralgia and diarrhea.

Subjects identified as responders to Amigal at the completion of the Phase 2 studies continued to maintain elevated levels of the target enzyme (a-Gal A), as measured in white blood cells, and reduced levels of the target substrate (kidney GL-3), as measured in urine.

A reduction of GL-3 levels was also observed in interstitial capillary cells from kidney biopsies. Previously reported Phase 2 results indicated that little to no GL-3 was detected in these cells in most subjects prior to treatment with Amigal. The new data were obtained from the retesting of biopsies using an improved methodology.

Preliminary results from the evaluation of modified doses and a new dosing regimen were also presented.

Derralynn
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
2. Amicus Therapeutics Announces Change to Board of Directors
3. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
8. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
9. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
10. Amicus Therapeutics Opens Research Facility in San Diego
11. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Acquisition Extends Elsevier,s Ability to Gather Global Healthcare News and, ... Increase ... Business Value for Customers, PHILADELPHIA, March 10 ... information, announced,today that it has acquired Windhover Information Inc., a ...
... March 10 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference ... at 2:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The live webcast can be accessed ...
... used by Avexa to select patients and optimize ... background therapy in phase III program, SOUTH SAN FRANCISCO, ... today that the Company,has signed an agreement with AVEXA Limited (ASX: ... technology in support of,Avexa,s drug discovery and development programs., Avexa ...
Cached Biology Technology:Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 2Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 2Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 4Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 5
(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...
(Date:6/18/2013)... a hacker lab. At Brandeis University, sophisticated computational ... helping scientists understand the complex interplay between genomic ... virus, outer "shell" critical for replication. ... we are finding will help researchers alter virus ... fellow Jason Perlmutter, first author of the scientific ...
(Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
Breaking Biology News(10 mins):Immunity mechanism discovered 2Computer modeling technique goes viral at Brandeis 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... Oct. 17, 2011 Dr. Randal Halfmann, a research ... 10 investigators selected for the first National Institutes of ... program allows creative early-career scientists to leapfrog the traditional ... investigations. The charter group of awardees will share approximately ...
... It is becoming more and more common to install ... but not all roofs are equally suitable. Scientists from the ... the actual conditions to determine the maximum possible magnitude of ... a particular roof. The scientists have surveyed Gothenburg in a ...
... 17 October 2011 - Genomatix is among the 41 ... European Commission as a high impact project within its ... generation sequencing data analysis and the development of an ... to researchers within and outside the consortium. "To ...
Cached Biology News:UT Southwestern biochemist receives new NIH Early Independence Award 2Now you can determine the solar efficiency of your roof 2
Rad51, N-terminal...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Biology Products: